orasur domin provid saliva collect
devic genet test leader oral fluid
diagnost rapid point care hiv hcv test
diagnost tool
opportun reiter buy pt
open trade low rang follow analyst downgrad
morn disagre rational downgrad find time
unusu amazon prime day today tomorrow big catalyst direct-
to-consum compani ancestri helix name three believ
bar set result look readili achiev believ outcom
strateg review may posit catalyst deni
uncertainti compani strateg review process think manag team
strong like explor option prior manag team may
thoroughli investig final think valuat support buy rate
stock trade rev poc peer group
broader peer group averag believ repres sneaki way
mega-growth driver buy-rat open
share mani custom mani small cap client buy
investor mandat recommend buy weak
dna day like surg april ancestri heavili
discount kit discount ancestri
discount recent show survey
american yet test interest get test estim
total american test american
amazon prime day kick hour last year two kit
sell product prime day discount price
kit appear look discount year
believ valu much profit margin kit
valu rapidli grow custom databas see grow interest
strateg review spoke new cfo roberto cuca morn indic
make progress strateg review process expect updat
call howev think execut plan could roll beyond august
ok us believ leav stone unturn like dive
deeper prior manag team dove think one divestitur
busi segment activ discuss contempl think
sharehold could reward own higher growth busi segment
play play look color progress deploy
net cash balanc sheet
like market penetr stori especi one triple-digit growth
investor tri figur much grow
blister growth rate molecular collect busi last year feel
good underli robust trend exceed forecast call
y/i growth wrote earlier quarter believ direct-to-consum
market penetr envis peopl genotyp
year last year note last month titl growth vector
point right takeaway road buy rais pt
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
growth catalyst molecular collect includ on-going growth direct-to-
consum test compani ancestri helix growth
compani global global popul sequenc project includ us
unit state look expans initi order saliva kit
million time growth compani gut microbiom busi
driven growth hiv ou y/i growth molecular collect
rev partial off-set overal declin infecti diseas busi
revenu grew robust y/i overal thank blister
y/i growth molecular collect segment
thought result like setup earn initi
revenue guid in-lin prior initi ep
guid includ charg final manag transit cost
model rev y/i comp gaap
ep adj ep model gm bake
declin gross margin year-over-year came
declin larg stem absenc royalti payment associ one lost
custom foreign govern hepat rapid test renew
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
diagnost tool
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin juli et
date time product juli et
pt base multipl rev discount three year discount rate
pt use premium multipl adj ep estim
pt use multipl revenu estim million discount back year discount rate
risk achiev target price valuat
regulatori risk exist new test indic delay denial approv would neg affect compani commerci risk
exist product reimburs competit continu weak economi could inhibit growth orasur drug
abus test busi risk associ intern sale infecti diseas product risk relat fund hiv
particularli unit state competit risk gener hiv product dna genotek subsidiari larg
custom failur continu work would advers impact busi
believ key risk includ major new product launch novaseq instrument premium valuat excess
peer group risk associ demand pace novaseq placement hiseq unit decommiss
competit noise/tract though believ meaning competit risk well bay nih/govern budgets/
spend particularli foreign govern like japan genom research center regulatori risk fda addit
risk factor less concern includ typic medic technolog risk price instrument consum risk
associ move test clinic increas compani focu bioinformat long-term also
highlight spend scale helix
invest risk includ larg varianc season respiratori product relat incid respiratori ill like
influenza accuraci annual influenza vaccin competit particularli establish molecular diagnost
compani product develop delay fda regulatori risk includ pma clia-waiv submiss emerg
altern over-the-count over-the-counter market new rapid molecular technolog cannib rapid test offer commerci risk
common medic technolog risk
diagnost tool
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
